GlassScriptPhysician profile
Rajesh Bhatnagar
NPI 1386605517
$16,395.67
in general payments reported to CMS, 2019-2025
53 companies · $2,720 in 2025
The $2,720 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,043 · 2020: $1,950 · 2021: $1,536 · 2022: $2,286 · 2023: $2,914 · 2024: $2,947 · 2025: $2,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,554 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17.93 · Education: $7.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,554.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17.93 |
| Education | $7.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,942.44 | 2019-2025 | Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $1,526.77 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Emd Serono, INC. | $1,296.49 | 2019-2025 | Mavenclad, Mavenclad |
| Mdd US Operations, LLC | $985.56 | 2019-2025 | Gocovri, Gocovri |
| Amneal Pharmaceuticals LLC | $803.17 | 2022-2025 | Crexont, Rytary, Ongentys |
| Eisai INC. | $779.17 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $763.19 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $743.25 | 2023-2025 | Rexulti, Abilify Maintena |
| Abbott Laboratories | $662.27 | 2019-2024 | Infinity |
| Biogen, INC. | $592.95 | 2019-2024 | Tysabri, Vumerity |
| Acadia Pharmaceuticals INC | $540.80 | 2019-2025 | Nuplazid, Daybue |
| Pfizer INC. | $526.77 | 2019-2025 | |
| Lundbeck LLC | $507.43 | 2019-2025 | Vyepti, Rexulti |
| Tg Therapeutics, INC. | $501.12 | 2024-2025 | |
| Kyowa Kirin, INC. | $385.15 | 2019-2024 | Nourianz |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Bhatnagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.